晚期电流的MOG1L18F介导的增加产生长QT综合征
Paula G Socuéllamos1,2, Juan Manuel Ruiz-Robles1, Francisco M Cruz1
1Spanish National Center for Cardiovascular Research (CNIC), Madrid, Spain.
medRxiv : the preprint server for health sciences
|December 25, 2025
概括
一种新型的MOG1变体 (L18F) 通过增加迟电流 (INaL) 和损害心脏导电,导致长QT综合征 (LQTS). 针对NaV1.8为这种LQTS亚型提供了潜在的治疗策略.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子心脏病学分子心脏病学
- 电子生理学 电子生理学
背景情况:
- SCN5A编码了NaV1.5通道,这些通道对心脏动作潜力至关重要;功能增益变异导致LQTS,功能丧失导致布鲁加达综合征.
- MOG1是一种NaV1.5通道体组件,增强NaV1.5电流和膜表达.
- 虽然MOG1功能丧失变体与布鲁加达综合征有关,但没有报告LQTS的相关性.
研究的目的:
- 调查在LQTS.患者中发现的一种新型MOG1变异 (p.18L>F) 的作用.
- 阐明MOG1 L18F变异对心脏电生理学的功能后果,并确定潜在的治疗点.
主要方法:
- 使用AAV9输送野生类型 (WT) 和L18F突变MOG1.1生成心脏特异性小鼠模型.
- 进行了表面心电图,编程电刺激,光学映射,补丁电生理学和分子分析.
- 使用NaV1.8抑制剂 (A-803467) 来评估其治疗潜力.
主要成果:
- MOG1 L18F试验对象在低血下表现出完整的AV阻塞,QT延长和腹腔心动减速.
- MOG1 L18F小鼠显示QT延长,心律不整的发病率增加,以及低血症状恶化.
- MOG1 L18F导致晚期电流 (INaL) 增加,动作潜力的持续时间升高,并触发了活性,NaV1.8抑制逆转了效应.
结论:
- MOG1 L18F变异代表了LQTS的新遗传原因,其特点是AV导电受损和INaL增加.
- 这种变异导致动作潜能持续时间和QT间隔延长,导致心律失常,特别是在低血的情况下.
- NaV1.8被确定为致病性INaL增加的调解者,也是这种MOG1相关的LQTS的潜在治疗标.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
Voltage-gated Ion Channels
10.2K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
10.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Antiepileptic Drugs: Potassium Channel Activators
590
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
590
Antiepileptic Drugs: Sodium Channel Blockers
1.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.5K
Regulation of Sodium and Potassium
1.9K
The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
1.9K


